Preoperative or Postoperative Therapy of Patients With Stages IB, II, IIIA Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
In this phase II study, we plan to evaluate several novel components of therapy. In patients
with potentially resectable stages IIB (T3N0) and IIIA we will compare weekly paclitaxel and
carboplatin with concomitant radiation therapy versus weekly paclitaxel and every 4 week
carboplatin in the preoperative (neoadjuvant) setting. For patients with potentially
resectable stage IB, IIA and IIB (T2N1) tumors, weekly paclitaxel and every 4 week
carboplatin will be given pre-operatively (neoadjuvant). The feasibility of resection will be
evaluated in the neoadjuvant group of patients. The continued study of concurrent radiation
therapy with weekly paclitaxel and carboplatin will be evaluated in those patients with stage
IIB (T3N0) and IIIA disease who initially had resection (adjuvant setting). Lastly, weekly
paclitaxel and carboplatin every 4 weeks will be evaluated as an adjuvant program in patients
who had completely resected stage IB, IIA and IIB (T2N1).